Stephen South, MD
Endocrinology, Diabetes & Metabolism · Greensboro, NCNPI 1043237472
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $564,250 of the $624,185 with a category attached, or 90.4%. Lilly USA, LLC accounts for 82.4% of it on its own, with 59 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,465 payments — averaging $426.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$514K
- Boehringer Ingelheim$37K
- Johnson & Johnson$29K
- Amgen$18K
- Madrigal Pharmaceuticals$11K
- Valeritas, Inc.$3K
- plus $11K from 54 others
What the payments were for
- Consulting fees$15,3352%
- Speaking & faculty fees$564,25090%
- Travel & lodging$23,5894%
- Food & beverage$20,7943%
- Education$1580%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRULICITY$213,738
- MOUNJARO$137,844
- JARDIANCE$131,935
- INVOKANA$27,980
- TEPEZZA$11,794
- REZDIFFRA$10,166
- V-GO$3,200
- CeQur Simplicity$944
- FARXIGA$352
- iLet Bionic Pancreas$346
- NEXLIZET$248
- NEXLETOL$248
- Kerendia$247
- InPen$150
- Minimed 630G$134
- DEXCOM G6 TRANSMITTER$128
- Vascepa$125
- TRELEGY ELLIPTA$123
- Ozempic$123
- RYBELSUS$123
How this compares
$624,185 in reported general payments places this provider in the 95th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 142 | $161,670 |
| TrulicityDulaglutide | 63 | $110,325 |
| MounjaroTirzepatide | 72 | $99,062 |
| EliquisApixaban | 76 | $78,606 |
| OzempicSemaglutide | 60 | $74,011 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 58 | $54,683 |
| ForteoTeriparatide | 12 | $50,449 |
| XareltoRivaroxaban | 32 | $42,198 |
| Tresiba Flextouch U-100Insulin Degludec | 58 | $41,500 |
| SynjardyEmpagliflozin/Metformin Hcl | 23 | $40,106 |
| Tresiba Flextouch U-200Insulin Degludec | 48 | $38,070 |
| MyrbetriqMirabegron | 66 | $35,710 |
| FarxigaDapagliflozin Propanediol | 32 | $35,508 |
| JanumetSitagliptin Phos/Metformin Hcl | 31 | $27,128 |
| SynthroidLevothyroxine Sodium | 255 | $26,428 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Forteo, Humalog | $514,345 | $266,491170 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Jentadueto Xr | $36,762 | $262,247235 claims |
| PfizerEliquis, Lyrica | $106 | $94,64391 claims |
| Novo NordiskOzempic, Novolog | $1,382 | $88,577124 claims |
| MerckJanumet, Januvia, Lagevrio (Eua) | $89 | $55,80859 claims |
| Johnson & JohnsonXarelto | $28,992 | $42,19832 claims |
| AstraZenecaFarxiga, Symbicort | $666 | $39,17646 claims |
| Astellas Pharma US IncMyrbetriq | $258 | $35,71066 claims |
| AbbVieSynthroid | $925 | $26,428255 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $67 | $10,59613 claims |
| GSKTrelegy Ellipta | $429 | $10,47116 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $90 | $8,925659 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Greensboro
- Mark WarrenGreenville$915K
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
- Michael FavoritoWilmington$723K
- Richard DoddAsheville$526K
- Wendy LaneAsheville$487K
- Victor MarlarAsheville$483K
- John BuseChapel Hill$460K
- Denis BeckerRaleigh$459K
- Charalambos DemetriStatesville$439K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.